We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

113 hedge funds and large institutions have $112M invested in Cymabay Therapeutics in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,591% more call options, than puts

Call options by funds: $930K | Put options by funds: $55K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

10% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 31

18% less funds holding

Funds holding: 137 → 113 (-24)

41% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 46

66% less capital invested

Capital invested by funds: $328M → $112M (-$216M)

Holders
113
Holders Change
-24
Holders Change %
-17.52%
% of All Funds
2.23%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
27
Increased
34
Reduced
31
Closed
46
Calls
$930K
Puts
$55K
Net Calls
+$875K
Net Calls Change
-$4.66M

Top Buyers

Rank Fund Capital Flow
1
ECM
Engine Capital Management
New York
+$18.7M
2
ACA
Avoro Capital Advisors
New York
+$10.5M
3
Morgan Stanley
Morgan Stanley
New York
+$7.54M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.99M
5
LP
LMR Partners
United Kingdom
+$3.35M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$29.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.2M
3
EAM
Eagle Asset Management
Florida
-$12M
4
CTA
Carillon Tower Advisers
Florida
-$10.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$9.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$761K +$1.35M +359,608 +1,253%
Goldman Sachs
27
Goldman Sachs
New York
$746K +$456K +121,371 +47%
Charles Schwab
28
Charles Schwab
California
$725K -$80.4K -21,394 -5%
Hudson Bay Capital Management
29
Hudson Bay Capital Management
Connecticut
$637K +$1.22M +325,000 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$551K +$61.2K +16,303 +6%
BCM
31
Bridgeway Capital Management
Texas
$544K +$1.04M +277,600 New
SIM
32
Spark Investment Management
New York
$529K – – –
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
$425K +$626K +166,759 +335%
WG
34
Winton Group
United Kingdom
$391K +$749K +199,381 New
GCP
35
GSA Capital Partners
United Kingdom
$387K +$568K +151,187 +328%
ARTA
36
A.R.T. Advisors
New York
$383K +$577K +153,541 +366%
AIM
37
Alambic Investment Management
California
$329K +$630K +167,839 New
PP
38
Paloma Partners
Connecticut
$319K +$612K +162,834 New
LOAMU
39
Lombard Odier Asset Management (USA)
New York
$284K – – –
A
40
Abingworth
United Kingdom
$256K – – –
Squarepoint
41
Squarepoint
New York
$240K -$835K -222,203 -64%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$238K +$455K +121,238 New
Swiss National Bank
43
Swiss National Bank
Switzerland
$232K +$9.39K +2,500 +2%
AllianceBernstein
44
AllianceBernstein
Tennessee
$229K – – –
PPA
45
Parametric Portfolio Associates
Washington
$225K -$250K -66,543 -37%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$217K +$18.4K +4,912 +5%
AC
47
Aristides Capital
Kentucky
$205K +$393K +104,651 New
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$203K – – –
Federated Hermes
49
Federated Hermes
Pennsylvania
$193K +$234K +62,185 +171%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$189K +$285K +75,800 +368%
1
2
3 4 5

CBAY Hedge Fund Activity: Q4 2019 in Review

113 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2019, worth a combined $112M — down 66% from $328M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of CBAY and 27 opened new positions — a net loss of 19 holders — while 31 trimmed existing stakes and 34 added.

The largest buyer was Engine Capital Management, opening a new position worth an estimated $18.7M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $29.2M sold.

  • 113 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2019, down from 137 in Q3 2019.
  • Funds reported $112M of Cymabay Therapeutics stock for Q4 2019, down 66% quarter-over-quarter.
  • 27 funds opened new Cymabay Therapeutics positions in Q4 2019 and 46 closed out, a net change of -19 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2019 was Engine Capital Management, an estimated $18.7M added.
  • The largest Cymabay Therapeutics seller in Q4 2019 was Baker Bros. Advisors, an estimated $29.2M sold.

Based on aggregated 13F filings for Q4 2019.